The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Causes & management of ibrutinib discontinuation in CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the causes for ibrutinib discontinuation in chronic lymphocytic leukemia (CLL), explaining how to manage this situation. Dr Scarfò explains that patients may discontinue this agent due to either intolerance or progression. While patients who progress on ibrutinib may be treated with venetoclax, patients who are intolerant to ibrutinib might either be followed up or treated with another covalent BTK inhibitor depending on their disease status. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly Speaker bureau: Octapharma
